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Abstract
Voltage gated potassium channels have been extensively studied in relation to cancer. In this review, we will focus
on the role of two potassium channels, Ether à-go-go (Eag), Human ether à-go-go related gene (HERG), in cancer
and their potential therapeutic utility in the treatment of cancer. Eag and HERG are expressed in cancers of various
organs and have been implicated in cell cycle progression and proliferation of cancer cells. Inhibition of these
channels has been shown to reduce proliferation both in vitro and vivo studies identifying potassium channel
modulators as putative inhibitors of tumour progression. Eag channels in view of their restricted expression in nor-
mal tissue may emerge as novel tumour biomarkers.
Introduction
Cancer is one of the major killers throughout the world.
It is estimated that a total of 1,529,560 new cancer cases
and 569,490 deaths from cancer will occur in the United
States in 2010 [1]. There is increasing evidence that ion
channels are involved in various processes characteristic
of cancer cells such as uncontrolled cell proliferation,
migration and survival in hypoxic conditions [2].
Ion channels are integral membrane proteins that
mediate the transfer of ions through the hydrophobic
lipid bilayer of the cell membrane. They play an impor-
tant role in a variety of functions that range from nerve/
muscle excitation [3], regulation of blood pressure [4],
through to sperm motility and capacitation [5]. Potas-
sium K
+channels comprise the largest family of ion
channels encoded by ~300 genes with phenotypic diver-
sity generated through alternative splicing, variable asso-
ciation of (homo/heteromultimerisation) of channel
subunits and posttranslational modifications. In normal
cellular function, K
+ channels are the main determinants
of a cell’s resting membrane potential. K
+ channels have
also been linked to cell volume control [6,7], cell cycle
progression[8] and cardiac repolarisation[9].
In recent years, expression of several K
+ channel sub-
types has been described in a plethora of malignancies.
In particular the role of voltage gated K
+ channels in
cancer, has been reviewed in several excellent publica-
tions [2,10,11]. This review will focus specifically on the
Eag and HERG voltage gated K
+ channels with their
potential therapeutic applications in cancer.
Historical perspective
The Eag gene, present on locus 50 of the X chromo-
some of the fruitfly Drosophila melanogaster,i sa
mutant of the Shaker gene [12], so called since flies
afflicted with this mutation exhibited slow, rhythmic
shaking of the legs with minimal shaking of wings or
abdomen on exposure to ether anaesthesia [13,14]. In a
bid to find homologous Eag genes in Drosophila and
mammals, a further two- Elk (Eag like gene) and Erg
(Eag related gene) were discovered. All members of the
Eag family have >85% DNA sequence homology [15].
The International Union of Basic and Clinical Pharma-
cology (IUPHAR) have classified the Eag family as
shown in Table 1. [16]
The Eag channel has also been cloned from rat (rEag)
[ 1 7 ] ,a n db o v i n er e t i n a[ 1 8 ] .T h ef i r s th u m a nE a g
(hEag), located on chromosome 1q 32-41, was cloned
from cultured myoblasts at the onset of fusion, but was
absent in adult skeletal muscle, [19,20] indicating that
expression of hEag is linked to the early stages of syncy-
tial myotube formation.
The human HERG gene was the first member of the
Ether-a go-go family to be isolated by screening of
human hippocampal cDNA with the mouse homologue
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also been implicated in Long QT Syndrome 2 [21].
Location and function of Eag and HERG
Eag channels are expressed in fusing myoblasts and
been posulated to have a role in their hyperpolarisation
that preceeds their fusion [19]. Eag channels are also
selectively expressed in the brain and placenta of rat
and humans [19,22], with diffuse immunohistochemical
reactivity in rat brain. They are very noticeable in the
perinuclear space of cells and proximal regions of the
extensions, both in rat and human brain. The real time
PCR analysis of rat brain revealed higher Eag 1 expres-
sion in olfactory bulb, cerebral cortex, striatum, hippo-
campus, hypothalamus, and cerebellum, and low
expression in thalamus and brainstem [23].
The function of Eag channels in neurotransmitter
release at the neuromuscular junctions to initiate action
potential in Drosophila melanogaster larvae is well
known [24] and recently genes for shal and shaker
channels in the central nervous system of Drosophila
melanogaster have been shown to be reciprocally regu-
lated resulting in a target dependent, homeostatic mod-
ulation of synaptic transmission [25]. Eag channels are
also involved in odour transduction [26] and are
encoded in seizure locus in Drosophila [27]. In mam-
mals, although Eag channels have been shown to be pre-
sent in rat brain, their exact physiological function is not
known, but in rat retina, they are known to be involved
in the dark current-loop of photoreceptors. [28].
In contrast to Eag channels, HERG channels are more
widely expressed and their functions differ according to
their localization (Table 2). The HERG channel has a
dominant presence in normal human myocardium
where it is involved in the repolarisation phase of the
cardiac action potential [21]. Mutations of this channel
causes long QT syndrome 2 leading to cardiac arrhyth-
mias and sudden death [29]. Gain of function mutations
in this channel lead to short QT syndrome and sudden
infant death [30].
Structure of Eag channel family
Members of the Eag family share the same structure of
other voltage-gated potassium channels, comprising of
four identical a subunits each consisting of six mem-
brane spanning domains (S1-S6) with cytoplasmic
amino (N) and carboxy (C) termini. The ion-conduction
pathway or pore region (P) is positioned between S5-S6,
with voltage being sensed predominantly by the chain of
positive arginine or lysine residues based at every third
position, separated by two hydrophobic residues within
the S4 domain which acts as a voltage sensor [31,32].
All the domains are well conserved among all the family
members of Eag namely Eag, HERG and Elk, including
the positively charged amino acids in the S4 segment
[15]. The N terminal consists of a Per-Arnt-Sim (PAS)
domain [33], a hypoxia sensor leading to the activation
of hypoxia inducible factor (HIF1), resulting in increased
glycolysis and angiogenesis thus conferring a selective
growth advantage to cancer cells in a hypoxic environment
[34,35]. The C terminus consists of a cyclic nucleotide
binding domain (cNBD) and tetramerization-coil-coil
domain with an Endoplasmic reticulum retention signal
(RXR), which is involved in the tetramerization and func-
tional expression of the channels [36,37]. Also present on
the C terminus are multiple signalling modules including
putative nuclear export sequences (NES) and nuclear loca-
lization sequences (NLS) with binding sites for calmodulin
(CaM), calcium/CaM-dependent protein kinaseII (CaM-
KII) [38]. These NES and NLS play an important role in
perinuclear localization of these channels.The structure of
Eag channels is well conserved in Drosophila,m o u s e ,r a t
and humans. The sequence comparisons among family
members has shown that two members of the same
subfamily in different species share about 60-70% amino
acid identities from S1 through to the cNBD segment [39].
Eag and HERG channels in cancer
The initial study reporting on a potential link between
the Eag family of channels and cancer showed that high
levels of herg mRNA were present in 17 cancer cell lines
of different species (human and murine) with distinct
histogenesis. These included neuroblastoma, rhabdo-
myosarcoma, adenocarcinoma, lung microcytoma, pitui-
tary tumours, insulinoma B cells and monoblastic
leukaemia [40].
Following this discovery, Walter Stuhmer’sg r o u p
showed that Chinese Hamster ovary (CHO) cells when
transfected with rEag exhibited a transformed cancerous
phenotype characterised by the ability of the cells to
grow in a low concentration (0.5%) of serum, displaying
increased DNA synthesis, higher metabolic activity and
Table 1 Members of the Eag family
Previous name Official IUPHAR name Human gene name
Eag1, KCNH1a,
Eag1a, Eag1b
Kv 10.1 KCNH 1
Eag2, KCNH5 Kv 10.2 KCNH 5
HERG, erg1, hergb Kv 11.1 KCNH 2
erg2 Kv 11.2 KCNH 6
erg3 Kv 11.3 KCNH 7
elk3, elk1 Kv 12.1 KCNH 8
elk2, BEC 1 Kv 12.2 KCNH 3
elk1, BEC 2 Kv 12.3 KCNH 4
Eag- ether à-go-go, HERG- Human ether à-go-go related gene, erg- ether à-
go-go related gene, elk- ether à-go-go like, BEC- Brain Eag-like channel, KCNH-
potassium channel H family.
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demonstrated that herg mRNA is also expressed in
MCF-7 (breast cancer), SHSY-5Y (neuroblastoma) and
He-La (carcinoma cervix) cell lines. Inhibition by anti-
sense oligonucleotides decreased the RNA content and
functional protein of EF119 (breast cancer) cells [22].
Furthermore subcutaneous implantation of CHO cells
expressing Eag channels in severe combined immune
deficiency (SCID) mice lead to aggressive tumours
showing intratumoral necrosis [22]. Eag channels also
appear to impart a selective advantage for tumour cells
in hypoxia by production of hypoxia inducible factor-1
(HIF-1) and thereby increasing vascular endothelial
growth factor (VEGF) and increased vascularisation [35].
Additionally expression of Eag channels has been shown
to be associated with re-organisation of the cytoskeleton
and extracellular matrix thereby influencing adhesion,
proliferation and metastasis of tumour cells [41]. These
experiments collectively demonstrate the oncogenic
potential of Eag channels and hence their activation in
cancer cells.
Eag channels have also been shown to have increased
expression in various cancer cell lines namely IGR1,
IPC298, and IGR39 (melanoma) [42], SH-SY5Y (neuro-
blastoma) [43] and MCF-7 (breast cancer) cell lines and
various cancers such as gliomas [44], cervical cancers
[45], colon carcinoma [46], gastric cancers [47] and sar-
comas [48].
HERG channels have been shown to be expressed in
various cell lines like human and murine neuroblastoma,
human leukaemia (preosteoclastic, lymphoblastic, myelo-
genous and promyelocytic) [49-51], human rhabdomyo-
sarcoma, colon carcinoma, mammary carcinoma,
squamous cervical, endometrial cancer, gastric and glio-
blastoma [52-55].
The first tissue expression of HERG channels in cancer
showed that herg mRNA and HERG protein was
expressed in 67 and 82% of endometrial cancer tissues
compared to 18% of normal endometrium with no
expression seen in endometrial hyperplasia [56]. The
same group also showed that both herg gene and HERG
protein were expressed in blast cells of acute myeloid leu-
kaemia patients while no expression was seen in periph-
eral blood mononuclear cells [57]. Similar results were
demonstrated in lymphocytic leukaemia with no HERG
expression in normal lymphocytes [51]. Prolactinoma
cells have been shown to express the herg transcript and
HERG channels have been suggested to a play a role in
prolactin secretion [58].
Further investigation of HERG channels in cancer
invasion and metastasis revealed that, in addition to the
high expression of herg gene and HERG protein in col-
orectal cancers, highest expression is seen in metastatic
cancers with absence in normal colon and adenomas.
HERG channels also modulate the invasiveness of colon
cancer thought to be directly related to the amount of
HERG protein present on the cell membrane [59] and
confirmed by HERG expression in gastric [60] and mel-
anoma cells [61]. Increasing expression is associated
with high grade tumours, furthermore knocking down
of herg gene by siRNA resulted in reduced proliferation
and invasiveness of the cells. In contrast high grade glio-
mas have shown lower expression of herg gene com-
pared to high grade tumours [44] while there is loss of
HERG expression in renal cell cancer compared to nor-
mal kidney [62].
These studies show that Eag and HERG channels are
expressed by a variety of cancer cell lines and tissues
with Eag channel showing an oncogenic potential while
HERG channels are associated with more aggressive
tumours and have a role in mediating invasion.
Eag in cancer prognosis
Eag has been shown to have high expression in colorec-
tal cancers compared to adenomas and its expression
correlates with tumour size, lymph node metastasis and
Dukes staging suggesting its role as a prognostic marker
[63]. Similar studies in gastric cancer have shown that
higher Eag expression is associated with higher stage
and lymph node metastasis, which are known poor
prognostic markers [47]. Recently Eag has been shown
to be present in acute myeloid leukaemia and the chan-
nel expression strongly correlated with increasing age,
higher relapse rates and significantly shorter survival
[64].
Regulation of Eag channels in cancer
Eag channels have been found to be up regulated in
mouse colon on treatment with chemical carcinogens
such as Dimethylhydrazine (DMH) and N-methyl-N-nitro-
sourea (MNU) compared to chemically induced Dextran
sulphate sodium (DSS) colitis. These carcinogens are well
Table 2 Location and function of HERG channel
Organ Function References
Heart Repolarisation of cardiac action potential [21,29,30]
CNS Maintain membrane potential and development of neurons of spinal cord and carotid glomus cells [92,93]
GIT Regulate motility of gut [94]
Endocrine system Secretion of insulin and modulating epinephrine release in chromaffin cells [95,96]
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mucosa. Moreover there was higher Eag protein expres-
sion and mRNA in the distal mouse colon treated by
DMH and MNU compared to the untreated proximal
colon which suggests their role in pathogenesis of colon
cancer [46]. Estrogen has also been shown to increase Eag
expression by its action on Estrogen receptor a (ERa)i n
cervical and lung carcinoma cells [65]. The same group
also showed that keratinocytes expressing HPV oncogene
expressed Eag compared to its lack of expression in nor-
mal keratinocytes. Higher Eag expression was also demon-
strated in cervical cancer cells containing high risk HPV16
and 18 [65]. Other factors that increased Eag expression
and activity are Insulin like growth factor-1 (IGF1) in
Breast (MCF-7) cells through the akt pathway [66] and
Arachidonic acid (AA)in melanoma cells [67].
Use of Eag expression as a potential tumour marker
The potential of using Eag channel expression as a tumour
marker is supported by observation that Eag channels
show higher expression in all patients with cervical cancer
[45]. In the normal group, there was higher expression in
patients with human papilloma virus (HPV) infection who
had negative smears and other premalignant conditions
such as atypical hyperplasia of endometrium and serous
cystadenoma of ovary. Moreover one patient with a nega-
tive smear had an unexpected finding of endocervical ade-
nocarcinoma with positive Eag expression at hysterectomy
suggesting its role as tumour marker and a potential early
predictor of cancer [45].
Injection of poly-lysine containing recombinant anti
Eag1 antibody conjugated to Cy5.5 into immune defi-
cient mice grafted with MBA-MB-435 S mammary can-
cer cell line clearly showed the tumour and the sentinel
lymph node on near infrared fluorescent imaging (NIF)
in 24 hours. [68].
The increased expression of Eag channel in the mouse
colon as a result of DMH exposure has been shown to
be associated with poor survival. Eag has also be shown
to be present at premalignant stage in the development
of colon cancer therefore Eag transcripts present in
stool samples and rectal biopsies may be useful as diag-
nostic and prognostic markers [46]. Thus Eag could be
potentially used as a tumour marker for various cancers.
The next question now arises: what is the role of these
channels in proliferation and cell cycle and how are they
associated with carcinogenesis? We have now started to
get some answers but still are quite far away from deter-
mining their exact role in carcinogenesis
Role of Eag and HERG channels in cell proliferation and
the cell cycle
The indication of an erg like inward rectifier being
involved in cell cycle came initially from neuroblastoma
cells that showed current characteristics resembling
those of erg channels with a rapid reduction in the cur-
rent when the cells were synchronised in G0/G1 phase or
G1/S boundary of the cell cycle [49]. This novel inward
rectifier also maintained the resting membrane potential
at a more negative value an important feature of cancer
cells[49]. Subsequently a slow activating potassium chan-
nel current similar to rat Eag (rEag) in neuroblastoma
cells (h-Eag) was characterised and it was demonstrated
that the electrical current was reduced to 5% of the con-
trol value when the neuroblastoma cells were synchro-
nised to G1 phase of the cell cycle on treatment of
retinoic acid, thus indicating their role in cell cycle [43].
Xenopus oocytes are a useful model for the study of
the cell cycle as they are indefinitely arrested in the G2
phase of the first meiotic cycle, until a hormonal stimu-
lus, for example progesterone, induces progression of
meiotic division. Rat Eag (rEag) channels expressed in
Xenopus oocytes reduce their activity when their
maturation is induced by progesterone and also by
Mitosis promoting factor as the oocytes progress
through the cell cycle, denoting that Eag channels are
cell cycle sensitive [69]. The partial syncronization of
Xenopus oocytes cells in G0/G1 or M phase greatly
increased the block by intracellular sodium (Na
+)a n d
caesium [70] which may be due to interaction of Eag
channels with microtubules which are depolymerised
during cell cycle [71]. Human Eag (hEag) has been
showed to be transiently expressed before myoblast
fusion and contribute to the hyperpolarisation that
drives the process. As myoblast fusion involves withdra-
wal from cell cycle to form skeletal muscle, Eag chan-
nels have been suggested to be involved in their cell
cycle regulation [19].
The expression of herg gene is not detectable in per-
ipheral blood mononuclear cells (PBMNC) and circulat-
ing CD34
+ cells, but then is rapidly expressed as soon as
they enter S phase on upon treatment with cytokine/
growth factor mixture, suggesting that HERG channels
play a role in cell cycle regulation [57]. Subsequently an
N-truncated herg1b isoform was shown to coexist with
herg1 RNA in human myeloid leukaemias. Both HERG1
and HERG1b proteins were demonstrated on the plasma
membranes and can form heterotetramers. The expres-
sion of these isoforms was found to oscillate during cell
cycle, with HERG1 protein upregulated in G1 phase and
down regulated in S phase, while the N truncated
HERG1b isoform upregulated in S phase [52]accounting
for the variations in HERG currents in the mitotic cycle
as shown in neuroblastoma cells [49].
The Eag and HERG channels have been shown to be
inhibited in tissues of varying histology by Eag and
HERG blockers which are reviewed in [10,11,72]. Imi-
pramine a known Eag blocker induces apoptosis in
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tion [73] while it has been shown that HERG expressing
cells are more sensitive to apoptosis induced by hydro-
gen peroxide, with reversal of effect on blocking with a
HERG blocker dofetilide [74]. The same authors also
showed co-expression of HERG and TNFa on cell
membrane of tumour cells, leading to increased activity
of the transcription factor nuclear factor kappa B facili-
tating tumour cell proliferation [74]. Thus both Eag and
HERG channels are associated with cell proliferation
and play an important role in modulation of cell cycle.
Hypothetical model of potential oncogenic mechanisms
(Summarised in Figure 1)
As we have discussed, there is considerable evidence
to support a role for Eag and HERG channels in cancer.
However it is not at all clear whether these channels
play causal roles in oncogenesis or whether the onco-
genic process results in aberrant expression and activa-
tion of the Eag channel family. Identifying the
mechanism underlying malignant transformation invol-
ving Eag channels especially is further compounded by a
lack of specific pharmacological agents. Despite these,
several theories have been advanced as to how Eag and
HERG channels could promote malignant transforma-
tion as discussed below:
It is well known that K
+ channels play an important role
in regulation of membrane potential in both excitable and
non excitable cells. Nilius eta l . [ 7 5 ] ,p r o p o s e dt h a ti n
human melanoma cells overexpression of K+ channels
leads to hyperpolarisation as a result of the efflux of
cations from the cell interior, which subsequently causes
Figure 1 Potential mechanisms of malignant transformation by K
+ channels. Increased expression of K
+ channels on cell membrane results
in increased influx of Ca
2+ ions resulting in increased transition of cells through G1/S phase of cell cycle. The channels in presence of hypoxia
lead to release of HIF1 and VGEF factor leading to increased angiogenesis and subsequent invasion and metastasis of tumours. The nuclear
localisation sequence (NLS) in the C terminus on activation results in perinuclear localisation of the channel leading to activation of Mitogen
activated protein kinase (MARP) pathway resulting in increased cell proliferation. The Eag channels also act through the Ca calmodulin pathway
to activate cell proliferation.
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2+ ions to maintain the membrane
potential. The role of Ca
2+ in the transition from the G1
to the S phase during mitosis in mammalian cells is well-
documented and Ca
2+ acts as a pacemaker that initiates
the timing of cell cycle transitions [76]. Therefore
increased intracellular Ca
2+ can trigger the rapid transition
of cells through the G1 to S phase leading to enhanced
proliferation. However the pathway through which this
Ca
2+ entry occurs is not known and change in resting
potential is not always observed when the cells are inhib-
ited by potassium channel blockers [77].
An alternative mechanism postulated concerns the
inverse relationship between cell volume and K
+ chan-
nels. Increasing K
+ channel activity leads to cell shrink-
age which then deforms the cell and modifies the
cytoskeletal components through changes in protein
kinases or phosphatases that control cell proliferation
[78]. This hypothesis is supported by the fact that K
+
channel blockers lead to an increase in cell volume and
inhibit proliferation. Howeve r ,i ti sa r g u e dt h a ta s t r o -
cytes that are involved in the formation of the blood
brain barrier [79], despite having high expression of K
+
channels undergo a reduction in cell volume in presence
of K
+ channel blockers while L-glutamate initiated K
+
influx into the cell leads to their swelling [80]
Hypoxia has been implicated as a stimulus for rapidly
growing tumours where, hypoxic areas lead to altered
cellular mechanisms consequently causing either an
increase in oxygen or activation of other mechanisms
not requiring oxygen. The induction of hypoxia induci-
ble factor (HIF-1a) by hypoxia, subsequently leads to
the transcriptional activation of genes encoding erythro-
poietin, VEGF and glycolytic enzymes, all thought to be
involved in various aspects of tumour initiation, growth
and metastasis [81]. HEK cells transfected with Eag
channels lead to increased production of HIF-a in
under hypoxic conditions and as Eag channels are over-
expressed in various cancers, they could potentially con-
fer selective advantage to cancer cells in hypoxic
conditions [35].
There has been increasing evidence linking mutant Eag
channels that contain non conducting subunits lacking
functional pore with cell proliferation. Hegle et al [82]
demonstrated the voltage dependent gating of the Eag
channel controlled the cell proliferation and Mitogen acti-
vated protein kinase (MAPK) signalling pathway by a
mechanism that is independent of K
+ influx through the
channel. Eag channels also act as a scaffold for and activate
Calcium -Calmodulin activated kinase II (CaMKII), form-
ing a complex which remains active even in the presence
of low calcium [83], leading to dysregulation of cell prolif-
eration and apoptosis resulting in genesis of cancer [84].
Activated Nuclear localization sequence (NLS) located
on the C terminus of Eag channels results in activation
of Mitogen activated protein kinase (MAPK) signal
transduction pathway that regulates cell morphology
[38]. Sarcoma and cervical cells [48,65] have been
shown to have increased perinuclear localization of Eag
channels and NLS may play an important role in its
oncogenic mechanism.
Therapeutic application
From the above studies it is clear that blocking Eag and
HERG channels inhibits cell proliferation and therefore
disease progression. These channels have been demon-
strated in the cell membrane by functional studies and
therefore are accessible targets for modulation by drugs.
Moreover Eag channels have restricted expression in the
central nervous system, placenta and in myoblasts just
prior to fusion but are expressed in cancer cell lines of
various origin and cancer tissues making them a poten-
tial marker and target for various drugs [10,19,22,85,86].
Both Eag and HERG belong to the same family of vol-
tage gated K
+ channels and share 47% of the amino acid
sequence [15]. Thus any drug acting on Eag channel
may also block HERG channels leading to prolonged
QT syndrome, cardiac arrhythmias and sudden death
[21,29]. Therefore there is a need for specific targeted
blockers for maximal inhibitory effect and reduction in
side effects.
Several approaches have been used to target or inhibit
Eag channels in cancer
1. Chemical blockers: Imipramine and astemizole
have been shown to abolish Eag currents and inhibit
the cell proliferation of tumour cells and are easily
available in the market for use [87,88]. However
both these drugs have undesirable cardiovascular
side effects due to HERG blockade which limits their
applicability in treating cancer.
2. Monoclonal antibodies: These act as highly speci-
fic molecules for a targeted blockade of the channels
and minimise the side effects associated with action
on homologous channels. These antibodies may also
be potentially used as vehicles for therapeutic agents
for a site specific action [86]. A monoclonal antibody
has been designed against Eag1 with no effect on
Eag2 and HERG channels. This antibody has been
shown to reduce the K
+ channel currents in isolated
cells and also inhibit the growth of cancer cells from
various organs both in vitro and vivo. Hence evi-
dence in favour of this antibody may potentially be
used either alone or in association with current
established treatment to reduce the dose and asso-
ciated side effects of conventional chemotherapeutic
drugs [89].
3. Inhibition of cell growth using small interfering
RNA (si RNA) technologies: This is a potential new
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the amount of protein that is produced. The activity
of Eag has been shown to be silenced by the use of
Eag specific siRNA which result in reduced protein
expression and inhibition of cell proliferation in var-
ious cancer cell lines with minimal non-specific side
effects [90]. The challenge with this approach is the
design of an appropriate transport vehicle and deliv-
ery of siRNA to the target organ and currently the
subject of intense research.
Targeting HERG channels
1. Short hairpin (sh) RNA technology: The knock
down of herg gene expression by the use of shRNAs
f o rH E R G 1a n dt h eH E R G - 1 bi s o f o r m ,r e d u c e d
growth rate, cell viability and inhibited colony for-
mation of neuroblastoma cells restricting them to
G0/G1 phase of cell cycle. There was also inhibition
of tumour cells injected into nude mice on treat-
ment with sh RNA. Thus this technology can be
potentially used in silencing of herg gene and subse-
quently the reduction in growth of tumour, but its
effect on the heart needs to be evaluated and the
delivery of these molecules to target organs still
poses a significant challenge [91].
2. Use of HERG blockers including E-4031 and erg-
t o x i nh a v es t i l ln o tb e e nt e s t e di nv i v os t u d i e sb u t
do show a promising role in potential use with che-
motherapeutic agents or in chemoresistant disease.
However tight cardiac monitoring will be needed
due to the development of drug induced Long QT
syndrome.
Conclusion
Both Eag and HERG channels have been shown to be
present in cancers of differing origin and have a role in
cell proliferation, progression and survival. There is
abundant data on the effects of various blockers on the
inhibition of cell growth and these channels may prove
to be promising novel therapeutic targets for the treat-
ment for cancer. They can be potentially be used in
conjunction with chemotherapeutic agents or can be
used in chemoresistant disease to improve survival. Eag
due to its restricted expression shows a promising role
as a potential tumour marker.
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